Latest news with #Karimi
Kuwait Times
5 days ago
- General
- Kuwait Times
Without reform, youth will inherit growing racism, classism: Expert
Professor urges redefining racism in line with regional realities, recognizing effect of external factors KUWAIT: A Kuwait University professor says thoughtful analysis and reform, especially in media and education, is needed to address the rise of racism in the Gulf. Dr Sawsan Karimi, a university professor specializing in Middle Eastern anthropology, said tackling racism requires defining what it means in the Gulf context. 'Is it the concept we use globally to address inhumane behavior, or is it something shaped by our own historical experience? Or is it a concept imposed on us externally?' she asks. She explains that the Western experience with racism, especially against black people, shaped much of the global discourse on racism due to Western dominance and their tendency to apply their standards universally. 'We didn't experience racism exactly in the same way, but that doesn't mean we are free from it. The concept itself is problematic and needs to be deconstructed to relate it properly to our historical and cultural context.' Current influences Today, Dr Karimi observes that racism in the Gulf is influenced heavily by regional religious, sectarian, and ethnic conflicts. 'We are not a closed society; we are influenced by external factors, including conflicts around us.' Social media platforms like TikTok and Instagram further feed these attitudes, especially among the youth. 'Our children's attitudes are shaped by what is superficially presented on these platforms. Because we are mainly consumers, not producers of content.' She warns that without real reform in media and education, which have the greatest impact on young minds, these issues will worsen. Wealth and classism Another key factor is the Gulf's rapid modernization and economic wealth. 'I think one of the biggest challenges we face is the effects of economic wealth on our socio-cultural structure,' she said. Dr Karimi explains how this has created an unhealthy form of classism that often outweighs ethnic or racial affiliations. 'Wealthy people tend to marry each other, even with different, let's say, ethnic affiliations. But a person of the same race will not take a very poor person,' Dr Karimi added. The Gulf is one of the world's most consumptive regions per capita—whether in water, food, or luxury goods,' she said, highlighting the rampant classism that people in the Gulf grapple with. 'Much of our wealth is spent on consumption, social status, and showmanship.' Dr Karimi stresses that the media and education system play a crucial role in addressing these issues and instilling the ethics of justice, equality, love, and cooperation. 'These are not new values for Gulf societies; our tradition of neighborliness is based on mutual support and social solidarity.' She advocates for media—such as popular soap operas—to actively preserve and promote these values through their narratives. Similarly, education must reinforce these ethics in tangible ways. 'What we sow now, we will reap soon. If the media and education systems do not change, the situation will deteriorate,' Dr Karimi warns. However, she remains optimistic: 'If we undertake a serious review and reform process, we can avoid future problems.'
Business Wire
22-05-2025
- Business
- Business Wire
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) announced today that it will present new research from its comprehensive development program evaluating its late-stage portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 in Chicago, Illinois. The presentations will include the first disclosure of results from a Phase 1/2 trial evaluating rinatabart sesutecan (Rina-S ®), an investigational folate receptor-alpha (FRa)-targeted, TOPO1-inhibor antibody-drug conjugate (ADC), in patients with recurrent/advanced endometrial cancer. Additionally, results from an analysis of the Phase 1/2 EPCORE NHL-1 study of epcoritamab, a T-cell–engaging bispecific antibody administered subcutaneously, including long-term follow-up in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who remain in complete response (CR) at 2 years, will be presented. 'Our presence at ASCO reflects our commitment to advancing our antibody science for patients in need of alternative treatment options, including women with endometrial cancers that have progressed following treatment with existing available therapies,' said Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab. 'We're particularly encouraged by Rina-S as a potential treatment option for endometrial cancer, one of the few cancers with rising mortality rates and few treatment options. Additionally, together with AbbVie, we are continuing our commitment to evaluating epcoritamab as a potential core therapy across B-cell malignancies.' Investor Update at ASCO 2025 On Monday, June 2 at 4:00 PM CDT (5:00 PM EDT/11:00 PM CEST), Genmab will host a review of the Rina-S data presented at ASCO. The event will be virtual and webcast live. Details, including the webcast link and registration, will be available on This meeting is not an official program of the ASCO Annual Meeting. All abstracts accepted for presentation have been published and may be accessed online via the ASCO Meeting Library. Abstracts accepted for presentation at ASCO include: Rinatabart sesutecan (Rina-S) Epcoritamab Abstract Number Abstract Title Type of Presentation Date/Time of Presentation 7043 Karimi et al. Novel analysis of 3-y results from the pivotal EPCORE NHL-1 study: Outcomes in patients with relapsed/refractory large B-cell lymphoma and complete response at 2 y with epcoritamab monotherapy Poster June 1; 9:00 a.m - 12:00 p.m. CDT e19001 Zhao et al. First data from phase 1b/2 EPCORE NHL-4: epcoritamab (epcor) in Chinese patients (Pts) with relapsed or refractory diffuse large B-cell lymphoma Publication NA Expand Non-Asset Abstract Number Abstract Title Type of Presentation Date/Time of Presentation 6046 Maghsoudi et al. Fusion of Radiomic, Pathomic, and Clinical Biomarkers Reveals Multi-scale Tumor Biology, Improves OS Stratification in HNSCC receiving Standard of Care (SOC) Poster June 2; 9:00 a.m.- 12:00 p.m. CDT Expand The safety and efficacy of investigational products and uses have not been established. About Rinatabart Sesutecan (Rina-S; GEN1184) Rinatabart sesutecan (Rina-S; GEN1184) is a FRα-targeted, TOPO1 ADC, currently being evaluated for the potential treatment of ovarian cancer and other FRα-expressing cancers. A Phase 3 trial (RAINFOL TM -02, NCT06619236) evaluating Rina-S in patients with platinum resistant ovarian cancer compared to treatment of investigator's choice is ongoing. In January 2024, the U.S. Food and Drug Administration granted Fast Track designation to Rina-S for the treatment of patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer. The safety and efficacy of rinatabart sesutecan has not been established. Please visit for more information. About Epcoritamab Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody ® technology and administered subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells. i Epcoritamab (approved under the brand name EPKINLY ® in the U.S. and Japan, and TEPKINLY ® in the EU) has received regulatory approval in certain lymphoma indications in several territories. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the investigational R/R FL indication and additional approvals for the R/R DLBCL indication. Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes five ongoing Phase 3, open-label, randomized trials including a trial evaluating epcoritamab as a monotherapy in patients with R/R DLBCL compared to investigators choice chemotherapy (NCT04628494), a trial evaluating epcoritamab in combination with R-CHOP in adult patients with newly diagnosed DLBCL (NCT05578976), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R2) in patients with R/R FL (NCT05409066), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R2) compared to chemoimmunotherapy in patients with previously untreated FL (NCT06191744), and a trial evaluating epcoritamab in combination with lenalidomide compared to chemoimmunotherapy in patients with R/R DLBCL (NCT06508658). The safety and efficacy of epcoritamab has not been established for these investigational uses. Please visit for more information. What is EPKINLY? EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, or follicular lymphoma (FL) that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children. IMPORTANT SAFETY INFORMATION Important Warnings—EPKINLY can cause serious side effects, including: Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or lifethreatening. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule. Neurologic problems that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. People with DLBCL or high-grade B-cell lymphoma should be hospitalized for 24 hours after receiving their first full dose of EPKINLY on day 15 of cycle 1 due to the risk of CRS and neurologic problems. Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. If you have any symptoms that impair consciousness, do not drive or use heavy machinery or do other dangerous activities until your symptoms go away. EPKINLY can cause other serious side effects, including: Infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell. Low blood cell counts, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems. Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects. Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY. In DLBCL or high-grade B-cell lymphoma, the most common side effects of EPKINLY include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea. The most common severe abnormal laboratory test results include decreased white blood cells, decreased red blood cells, and decreased platelets. In follicular lymphoma the most common side effects of EPKINLY include injection site reactions, CRS, COVID-19, tiredness, upper respiratory tract infections, muscle and bone pain, rash, diarrhea, fever, cough, and headache. The most common severe abnormal laboratory test results include decreased white blood cells and decreased red blood cells. These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at (800) FDA-1088 or or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622). Please see Medication Guide, including Important Warnings. Globally, prescribing information varies; refer to the individual country product label for complete information. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines ®. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit and follow us on LinkedIn and X. This Media Release contains forward looking statements. The words 'believe,' 'expect,' 'anticipate,' 'intend' and 'plan' and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab ®; the Y-shaped Genmab logo ®; Genmab in combination with the Y-shaped Genmab logo ®; HuMax ®; DuoBody ®; HexaBody ®; DuoHexaBody ®, HexElect ® and KYSO ®. EPCORE ®, EPKINLY ®, TEPKINLY ® and their designs are trademarks of AbbVie Biotechnology Ltd. i Engelberts PJ, et al. DuoBody-CD3xCD20 Induces Potent T-Cell-Mediated Killing of Malignant B Cells in Preclinical Models and Provides Opportunities for Subcutaneous Dosing. EBioMedicine
Yahoo
16-05-2025
- Yahoo
Shop owner sold illegal tobacco as well as vapes to underage children
A shop owner sold illegal tobacco as well as vapes and alcohol to underage children. Following an investigation by East Sussex Trading Standards, Lhon Karimi, 29, of Devonshire Road in Hastings, was sentenced to 12 weeks imprisonment, suspended for 12 months, given a £230 fine and ordered to pay £500 costs at Hastings Magistrates Court on April 24. The offences, which took place in 2023 and 2024, concerned illegal tobacco and cigarettes offered for sale as well as underage alcohol and vape sales at Karimi's shop Delboys in Castle Street in Hastings. East Sussex Trading Standards inspected the premises in May 2023 after a child test purchaser was able to buy a can of cider from the store. Counterfeit cigarettes and cigarettes and tobacco in non-standardised packaging were discovered. Hidden vapes found by the inspectors (Image: ESCC) A packet of illegal cigarettes was also sold by Karimi to an adult test purchaser in September 2023. A second inspection of the shop in April 2024, following the sale of an illegal over capacity vape to a child test purchaser the week before, resulted in the discovery of more illegal cigarettes. After initially pleading not guilty to all the charges put to him at court appearances throughout 2024, Karimi changed his plea at the start of his trial in December last year. Karimi pleaded guilty to five counts of breaching the Trade Marks Act, two counts of supplying tobacco in non-standardised packaging and one count each of breaching the Licensing Act and breaching the Children and Families Act. At the sentencing hearing last month, the court noted there was 'some ignorance and naivety' on Karimi's part and that he pleaded guilty once he understood the offence. Hidden cigarettes and tobacco in the shop (Image: ESCC) READ MORE: Constance Marten calls time on her evidence on her baby girl's death The court also made an order for the forfeiture and destruction of all the stock seized. Councillor Penny di Cara, the county council's lead member for economy, said: 'Whilst this case has taken some time to reach a conclusion, hopefully the prosecution and conviction will make it clear we will pursue offenders through the courts. 'We take the supply of illegal tobacco very seriously. The sale of cheap tobacco is widely acknowledged to negatively affect communities and encourage smoking among young people due to cheaper prices, as well as undermining the efforts of stop smoking services. 'The sale of alcohol and vapes to our young people is unacceptable and potentially exposes them to the addiction and health risks associated with the underage use of nicotine and alcohol.'
NDTV
08-05-2025
- Entertainment
- NDTV
Mandana Karimi Says "Proud Of India" After Backlash On Operation Sindoor Post, Calls For Deportation To Iran
New Delhi: Iranian model and actor Mandana Karimi has drawn criticism from several Internet users following her Instagram Story referring to Operation Sindoor. The post, which has now disappeared from her profile, mentioned India's pre-dawn retaliatory strikes on terror camps in Pakistan and alleged civilian casualties. She wrote, "The world is on fire, India bombing Pakistani Kashmir, murdering civilians and children moments ago. Israel murdered a family in Khan Yunis just moments ago. America bombed Yemen, murdering civilians just yesterday." She further stated, "All of these deaths are a direct response from genocidal powers that learned from each other that you can carry out war crimes with impunity while the world swallows its tongue. Whether it's Zionism, Hindutva fascism or American exceptionalism, imperialism continues to rage on and burn all in its path." The comments sparked outrage online, with many users asking Karimi to "go back to her own country." Karimi, who moved to India from Iran and has worked in the Indian film and modelling industry for years, has now shared a follow-up post responding to the backlash. In her latest Instagram post, she wrote, "Let me say this loud and clear: I've lived in India for 16 years. I've worked hard, adapted, contributed, and made this place my home-with love, effort, and respect. And yes, I've had the most incredible friends and people here who made me feel like I belong. But then there's the other side-the small-minded, toxic corner that will always see me as an outsider, no matter what I do (sic)." She added, "Here's the thing: I've always been open, vocal, and woke. But if I choose not to speak about something, not to post about something - that's also my right. It's a human right. You don't get to tell me when to speak, what to say, or how to feel. That's not how it works (sic)." Karimi clarified that her original message was intended to promote peace and not target any religion or political ideology. She also expressed disappointment at the online hate she received and said she remains proud of her adopted country. "And now, let's talk facts. I'm proud of India. I'm proud of how far this country has come. I have deep respect for the Indian government-for what it's done to protect its borders, grow its economy, and stand tall on the global stage. This country has given me space, purpose, and pride. And instead of standing together in that spirit, some people just want to tear down, hate, and harass (sic)," she said. The actress has now deleted this post. Mandana Karimi, who was seen in the Anil Kapoor-starrer Thar, came to India for her modelling and acting career, which would have been difficult to pursue under the conservative laws of Iran. While Karimi alleged civilian casualties in her original post, the Indian government claimed that its strikes were precise and targeted only terror infrastructure. The operation was in response to a terror attack in Pahalgam last month, which claimed 26 lives. Internationally designated terrorist Masood Azhar later confirmed that members of his family were killed in the strike. During the operation, Indian forces targeted nine terror sites across different regions in Pakistan. Meanwhile, Iran had offered to mediate peace talks between India and Pakistan before the May 7 strikes took place.
India Today
08-05-2025
- Entertainment
- India Today
Proud of India, have deep respect for government: Mandana Karimi after backlash
Iranian model and actor Mandana Karimi has outrage from several Indians after her Instagram story mentioning Operation Sindoor. Now, she has shared a post on how faceless Instagram accounts have been asking her to go back to her own country, and clarified that she is "proud of India" and has "deep respect for the Indian government."Her earlier post mentioned "India bombing Pakistan and murdering civilians and children." In her latest post, Karimi stated that her message was intended to promote peace, not to delve into religious or political issues. She expressed disappointment over the hate she received from anonymous accounts, urging her to return to her then wrote, "Let me say this loud and clear: I've lived in India for 16 years. I've worked hard, adapted, contributed, and made this place my home—with love, effort, and respect. And yes, I've had the most incredible friends and people here who made me feel like I belong. But then there's the other side—the small-minded, toxic corner that will always see me as an outsider, no matter what I do (sic)." "Here's the thing: I've always been open, vocal, and woke. But if I choose not to speak about something, not to post about something—that's also my right. It's a human right. You don't get to tell me when to speak, what to say, or how to feel. That's not how it works (sic)," Karimi also stated, "And now, let's talk facts. I'm proud of India. I'm proud of how far this country has come. I have deep respect for the Indian government—for what it's done to protect its borders, grow its economy, and stand tall on the global stage. This country has given me space, purpose, and pride. And instead of standing together in that spirit, some people just want to tear down, hate, and harass (sic)."advertisementHere is the post:The controversy arose following India's launch of 'Operation Sindoor' on Wednesday, where nine terrorist bases in Pakistan and Pakistan-occupied Kashmir were destroyed. This tri-services operation by the Army, Navy, and Air Force was a response to the Pahalgam terrorist attack. While many celebrities praised the operation and expressed pride in the Indian Armed Forces, Mandana Karimi's comments sparked outrage. Her post, which highlighted global conflicts and criticised imperialism, was met with severe criticism. Some users demanded her deportation, questioning her stay in has worked as an actor and model, with projects like 'Kya Cool Hai Hum 3' in her filmography. She has now quit Watch
